@ScottWaudbyHaemResLeics retweeted
Pleased to share some new PhD opportunities advertised within LCRC @uniofleicester to start this year including one within our institute le.ac.uk/study/research-degr… @HaemResLeic
@ScottWaudbyHaemResLeics retweeted
Harriet Walter (Leicester ECMC) is a co-author on a Phase I/II study looking at EZH2/EZH1 inhibitor in solid tumours or hematologic malignancies & reporting preliminary Phase II results at #ASCO23. Check out abstract #3094, poster #292 at 8 AM – bit.ly/3WEeh7k
@ScottWaudbyHaemResLeics retweeted
Great day for @HaemResLeic with @isogenicaltd and other university colleagues yesterday supported by @IPH_UK @uniofleicester @uolcollegecourt working on existing funding awards @UKRI_News @Impact_Aim_Mrc and building new collaborations.
@ScottWaudbyHaemResLeics retweeted
Congratulations to the @uniofleicester who have successfully renewed their bid to host an #NIHR-#CRUK Experimental Cancer Medicine Centre. The #ECMC works alongside our Hope Cancer Trials Centre @Leic_hospital to develop and deliver the latest cancer treatments for patients.
@ScottWaudbyHaemResLeics retweeted
Thank you Dr Matt Ahearne for taking the time to talk to us 💙
Hope Against Cancer works in partnership with local universities and hospitals to make sure that Leicestershire is a hub of expertise in cancer research and treatment.
hopeagainstcancer.org.uk/
Looking for a PhD on blood cancer? Wonder how T cells fitness could predict response to immunotherapy? We have an exciting MRC AIM iCase PhD project using a multi-omics approach more.bham.ac.uk/mrc-aim/phd-… application deadline: 9th January 2022.
We have an exciting opportunity for a MSc or PhD to join us as a Research Assistant to evaluate a novel therapeutic agent in blood cancer
jobs.le.ac.uk/vacancies/3881…
@ScottWaudbyHaemResLeics retweeted
A new, chemotherapy-free treatment for chronic lymphocytic leukaemia (CLL) is to be available on the NHS, it has been announced. https://teapawt.org/t.co/rgi8AXJ38k
@ScottWaudbyHaemResLeics retweeted
📰 IN THE NEWS: Researchers from the Leicester Cancer Research Centre have helped develop a genetic test to predict a common type of leukaemia (via @leicslive).
Read more 👇
leicestermercury.co.uk/news/… #CitizensofChange
@ScottWaudbyHaemResLeics retweeted
Following the Hope Cancer Trials Centre's expansion, here is what Professor Anne Thomas, the clinical lead for the centre, has to say ⬇️
Thank you everyone who has supported us and contributed to our cause 💙
#charity #fundraising #donate #nonprofit #support
Breaking News: we have an exciting translational iCase PhD project available @HaemResLeic @uniofleicester to work in collaboration with @isogenicaltd to develop and assess novel therapeutic antibodies for treatment of lymphoma. @ImpactMrc
more.bham.ac.uk/mrc-impact/p…
@ScottWaudbyHaemResLeics retweeted
Do join @DrChrisPFox, @MJAhearne, Prof Tim Illidge & myself at what should be a fascinating symposium on T-cell lymphoma. New @BritSocHaem guidelines on PTCL soon, so v timely. 3 scintillating talks & hopefully a lively Q&A. So get the coffee on and join us 8am, 12th November!
@ScottWaudbyHaemResLeics retweeted
And here it is 😁 👇
teapawt.org/bloodcancer_uk/status/…
To kick-start #BloodCancerAwarenessMonth we challenged our chief executive @GemmaPeters to channel @JacindaArdern and speed through 60 years of beating blood cancer in *TWO MINUTES*!
Does she manage it?? Watch now ⏱️👀👇
60 years of beating blood cancer in 2 minutes
We challenged our chief executive to speed through 60 years of beating blood cancer in *TWO MINUTES*! Does she manage it? ⏱️👀👇
Vikki's paper is out in Haematologica's August issue. A massive piece of work looking at the dependency of different BCL-2 family proteins for survival in DLBCL and their potential use as therapeutic targets.
Congratulations to all authors! @viklarr @MartinJSDyer Meike Vogler
In #DLBCL, the heterogeneous response to #BH3-mimetics is mediated by selective interactions between BAX, BAK and anti-apoptotic #BCL-2 proteins.
buff.ly/31frJSZ
Patients with blood cancer could be offered a tailored course of treatment in the future, after Leicester academics successfully trialled the use... le.ac.uk/news/2020/july/bloo…
Coming from around UK, from around the World but all @HaemResLeic so proud to work @uniofleicester and to live in this vibrant city #TogetherInHope #WeAreLeicester
3
@ScottWaudbyHaemResLeics retweeted
Leicester is an incredible city. There is so much diversity and unity in one place. It’s more important now than ever to come together and shine a light on what is great about our city. Let us shape our future together. #TogetherInHope #WeAreLeicester
This study confirms the promising efficacy of tirabrutinib both as monotherapy or in combination with other BCR signaling pathway inhibitors. 6 patients treated @Leic_hospital at the Hope Clinical Trial Facility @MartinJSDyer @HarrietSWalter @hopeagnstcancer
Results of the Phase Ib Study using Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia are now published. clincancerres.aacrjournals.o…
Results of the Phase Ib Study using Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia are now published. clincancerres.aacrjournals.o…
@ScottWaudbyHaemResLeics retweeted
Herein, the Authors review the current understanding of #CD20function, and the mechanisms of its regulation in normal and malignant #Bcells, highlighting the therapeutic implications.
buff.ly/3h5UnNr





















